Aurisco Pharmaceutical Co Ltd (605116) — Financial Flexibility Index
Aurisco Pharmaceutical Co Ltd (605116) has a Financial Flexibility Index of 0.56x as of December 2024. Free cash flow of CN¥872.68 Million (operating CF CN¥332.41 Million minus capex CN¥540.28 Million) represents 1% of total liabilities (CN¥1.55 Billion). Check 605116 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Aurisco Pharmaceutical Co Ltd Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Aurisco Pharmaceutical Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see Aurisco Pharmaceutical Co Ltd cash conversion from operations.
Annual Financial Flexibility Index for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year free cash flow to debt coverage for Aurisco Pharmaceutical Co Ltd. Explore 605116 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.56x | CN¥872.68 Million | CN¥332.41 Million | CN¥1.55 Billion | ▼ -50.4% |
| 2023 | 1.14x | CN¥691.08 Million | CN¥385.61 Million | CN¥607.03 Million | ▲ +3.7% |
| 2022 | 1.10x | CN¥382.63 Million | CN¥166.41 Million | CN¥348.68 Million | ▼ -48.2% |
| 2021 | 2.12x | CN¥452.19 Million | CN¥201.57 Million | CN¥213.44 Million | ▼ -16.0% |
| 2020 | 2.52x | CN¥373.28 Million | CN¥214.48 Million | CN¥147.98 Million | ▲ +22.9% |
| 2019 | 2.05x | CN¥252.38 Million | CN¥179.90 Million | CN¥122.96 Million | ▲ +34.0% |
| 2018 | 1.53x | CN¥203.91 Million | CN¥109.77 Million | CN¥133.16 Million | ▼ -9.7% |
| 2017 | 1.70x | CN¥224.51 Million | CN¥117.91 Million | CN¥132.44 Million | — |